Douglas Darden

Douglas Darden

Auto-generated profile, based on publicly available information

Douglas Darden

Kansas City Heart Rhythm Institute, Overland Park, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in JACC
Verified
Journal Article
Closed access
JHJonathan C. Hsu
Jonathan C. Hsu
DDDouglas Darden
Douglas Darden
CDChengan Du
Chengan Du
JMJoseph E. Marine
Joseph E. Marine
SNSheila Nichols
Sheila Nichols
PKPeter R. Kowey
Peter R. Kowey

1 March 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
OAOmar M. Aldaas
Omar M. Aldaas
FLFlorentino Lupercio
Florentino Lupercio
DDDouglas Darden
Douglas Darden
PMPraneet S. Mylavarapu
Praneet S. Mylavarapu
CMChaitanya L. Malladi
Chaitanya L. Malladi
JHJonathan C. Hsu
Jonathan C. Hsu

15 September 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
OAOmar M. Aldaas
Omar M. Aldaas
CMChaitanya L. Malladi
Chaitanya L. Malladi
PMPraneet S. Mylavarapu
Praneet S. Mylavarapu
FLFlorentino Lupercio
Florentino Lupercio
DDDouglas Darden
Douglas Darden
JHJonathan C Hsu
Jonathan C Hsu

1 July 2021 in Heart Rhythm
Verified
Journal Article
Closed access
DDDouglas Darden
Douglas Darden
JHJonathan C. Hsu
Jonathan C. Hsu
WTWendy S. Tzou
Wendy S. Tzou
JAJohannes C. von Alvensleben
Johannes C. von Alvensleben
MBMary Brooks
Mary Brooks
EAEric Adler
Eric Adler

19 October 2023 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
DDDouglas Darden
Douglas Darden
MMM. Bilal Munir
M. Bilal Munir
SZSarah Zimmerman
Sarah Zimmerman
MEMichael Eskander
Michael Eskander
NPNaga Venkata K. Pothineni
Naga Venkata K. Pothineni
JHJonathan C. Hsu
Jonathan C. Hsu

7 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
LMLydia Fekadu Messele
Lydia Fekadu Messele
MKMuhammad Zia Khan
Muhammad Zia Khan
DDDouglas Darden
Douglas Darden
SASiddharth Agarwal
Siddharth Agarwal
SKSatyam Krishan
Satyam Krishan
MMMuhammad Bilal Munir
Muhammad Bilal Munir
To determine outcomes in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion (LAAO) based on the underlying stroke risk (defined by the CHA2DS2-VASc score). Data were extracted from the National Inpatient Sample for calendar years 2016–20. Left atrial appendage occlusion implantations were identified on the basis of the International Classification of Diseases, 10th Revision, Clinical Modification code of 02L73DK. The study sample was stratified on the basis of the CHA2DS2-VASc score into three groups (scores of 3, 4, and ≥5). The outcomes assessed in our study included complications and resource utilization. A total of 73 795 LAAO device implantations were studied. Approximately 63% of LAAO device implantations occurred in patients with CHA2DS2-VASc scores of 4 and ≥5. The crude prevalence of pericardial effusion requiring intervention was higher with increased CHA2DS2-VASc score (1.4% in patients with a score of ≥5 vs. 1.1% in patients with a score of 4 vs. 0.8% in patients with a score of 3, P < 0.01). In the multivariable model adjusted for potential confounders, CHA2DS2-VASc scores of 4 and ≥5 were found to be independently associated with overall complications [adjusted odds ratio (aOR) 1.26, 95% confidence interval (CI) 1.18–1.35, and aOR 1.88, 95% CI 1.73–2.04, respectively] and prolonged length of stay (aOR 1.18, 95% CI 1.11–1.25, and aOR 1.54, 95% CI 1.44–1.66, respectively). A higher CHA2DS2-VASc score was associated with an increased risk of peri-procedural complications and resource utilization after LAAO. These findings highlight the importance of patient selection for the LAAO procedure and need validation in future studies.